While there are some legitimate concerns that Alexion's core franchise Soliris will eventually see competition from the likes ofApellis Pharmaceuticals (APLS)andRa Pharmaceuticals (RARX), which was recently acquired; they seem very overblown. The company is making good progress transitioning ov...